Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Assets Average: 2018-2025

Historic Assets Average for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to $1.2 billion.

  • Crinetics Pharmaceuticals' Assets Average rose 32.71% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 32.71%. This contributed to the annual value of $1.0 billion for FY2024, which is 109.61% up from last year.
  • Crinetics Pharmaceuticals' Assets Average amounted to $1.2 billion in Q3 2025, which was down 6.24% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Assets Average registered a high of $1.4 billion during Q1 2025, and its lowest value of $173.5 million during Q1 2021.
  • Its 3-year average for Assets Average is $872.3 million, with a median of $936.5 million in 2024.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Assets Average decreased by 19.57% in 2023 and then spiked by 215.13% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Assets Average (Quarterly) stood at $280.2 million in 2021, then surged by 31.53% to $368.5 million in 2022, then soared by 73.24% to $638.4 million in 2023, then skyrocketed by 85.76% to $1.2 billion in 2024, then soared by 32.71% to $1.2 billion in 2025.
  • Its Assets Average was $1.2 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.